Checkmate Pharmaceuticals, Inc. announced the appointment of Alan Bash as Chief Executive Officer, effective March 1, 2022. Mr. Bash, who will also join the Board of Directors, will succeed Alan Fuhrman, who has served as interim President and Chief Executive Officer since October 2021. Mr. Fuhrman will continue to serve Checkmate as a member of the Board of Directors.

Mr. Bash, age 50, has served in various roles of increasing responsibility at Bristol Myers Squibb (“BMS”) over the last 22 years. He is currently Senior Vice President, Commercial Model Innovation, at BMS. Prior to this role, he was Senior Vice President, Head of Commercial for Immunology and Fibrosis, and prior to that he served as Vice President, Worldwide Immuno-Oncology Commercialization at BMS.